首页 > 市场调查报告书 > 製药

药物开发开发业务受託机关

市场调查报告书

商品编码

1489248

全球製药 CDMO 市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Pharmaceutical CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球医药 CDMO 市场需求预计将从 2023 年的 1,794.7 亿美元达到近 3,516.4 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 7.76%。

製药CDMO（合约开发和製造组织）为製药公司提供全面的服务，包括药物开发、製造和包装。这些组织从药物配方的初始阶段到大规模生产和分销为製药公司提供支援。 CDMO 提供药物生命週期各个方面的专业知识，包括临床试验、法规遵循和品质控制。与 CDMO 合作使製药公司能够利用专业知识和基础设施，加快上市时间并降低成本，同时确保药品生产的高安全性和有效性标准。

市场动态

製药 CDMO（合约开发和製造组织）市场的成长是由製药外包需求不断增长推动的，因为公司寻求简化营运、降低成本并专注于研究和行销等核心能力。药物开发的复杂性以及对专业技能和设备的需求导致许多製药公司依赖 CDMO 进行开发和製造流程。此外，生物製剂和生物相似药生产的成长大大增加了对製药 CDMO 的需求，因为这些复杂的分子需要专门的製造能力。製造流程的技术进步，例如连续製造和一次性技术，进一步增强了 CDMO 的吸引力。

个人化医疗和利基疗法的成长趋势也有助于市场成长，因为这些需要 CDMO 可以提供的灵活且可扩展的生产解决方案。此外，监管压力和遵守严格品质标准的需求使 CDMO 对于寻求降低风险和确保产品品质的製药公司来说是一个有吸引力的选择。新兴市场製药业的不断扩张和药物开发投资的增加推动了製药 CDMO 市场的发展。然而，监管合规挑战和竞争压力可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球製药 CDMO 市场的各个细分市场进行了包容性评估。製药 CDMO 产业的成长和趋势为本研究提供了整体方法。

市场区隔

製药 CDMO 市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按申请

传染性疾病
肿瘤学
神经系统疾病

按工作流程

商业的
临床

按产品分类

合成
製造业
药物
应用程式介面

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的製药 CDMO 市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。医药CDMO市场的主要参与者包括药明康德、康泰伦特公司、艾伯维合约製造公司、龙沙集团、赢创工业股份公司、Patheon、Siegfried Holding AG、Recipharm AB、Aenova Group、CordenPharma、Jubilant Life Sciences Ltd.、Almac Group ，Piramal Pharma Solutions，Cambrex Corporation，法雷瓦。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：製药 CDMO 公司的竞争格局

医药CDMO市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
WuXi AppTec

公司简介
公司收入
产品
最近的发展

Catalent Inc.

公司简介
公司收入
产品
最近的发展

AbbVie Contract Manufacturing

公司简介
公司收入
产品
最近的发展

Lonza Group AG

公司简介
公司收入
产品
最近的发展

Evonik Industries AG

公司简介
公司收入
产品
最近的发展

Patheon

公司简介
公司收入
产品
最近的发展

Siegfried Holding AG

公司简介
公司收入
产品
最近的发展

Recipharm AB

公司简介
公司收入
产品
最近的发展

Aenova Group

公司简介
公司收入
产品
最近的发展

CordenPharma

公司简介
公司收入
产品
最近的发展

Jubilant Life Sciences Ltd.

公司简介
公司收入
产品
最近的发展

Almac Group

公司简介
公司收入
产品
最近的发展

Piramal Pharma Solutions

公司简介
公司收入
产品
最近的发展

Cambrex Corporation

公司简介
公司收入
产品
最近的发展

Fareva

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114744

The global demand for Pharmaceutical CDMO Market is presumed to reach the market size of nearly USD 351.64 Billion by 2032 from USD 179.47 Billion in 2023 with a CAGR of 7.76% under the study period 2024-2032.

A pharmaceutical CDMO (Contract Development and Manufacturing Organization) provides comprehensive services to pharmaceutical companies, including drug development, manufacturing, and packaging. These organizations support pharmaceutical firms from the initial stages of drug formulation to large-scale production and distribution. CDMOs offer expertise in various aspects of the drug lifecycle, including clinical trials, regulatory compliance, and quality control. Partnering with a CDMO allows pharmaceutical companies to leverage specialized knowledge and infrastructure, accelerating time-to-market and reducing costs while ensuring high safety and efficacy standards in drug production.

MARKET DYNAMICS

The growth of the pharmaceutical CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for pharmaceutical outsourcing, as companies seek to streamline operations, lower costs, and focus on core competencies such as research and marketing. The complexity of drug development and the need for specialized skills and equipment has led many pharmaceutical companies to rely on CDMOs for development and manufacturing processes. Additionally, the rise in biologics and biosimilar production has significantly boosted the demand for Pharmaceutical CDMOs, as these complex molecules require specialized manufacturing capabilities. Technological advancements in manufacturing processes, such as continuous manufacturing and single-use technologies, have further enhanced the appeal of CDMOs.

The growing trend towards personalized medicine and niche therapeutics also contributes to market growth, as these require flexible and scalable production solutions that CDMOs can provide. Moreover, regulatory pressures and the need for compliance with stringent quality standards make CDMOs an attractive option for pharmaceutical companies looking to mitigate risks and ensure product quality. The expanding pharmaceutical industry in emerging markets and increased investment in drug development drive the pharmaceutical CDMO market. However, regulatory compliance challenges and competitive pressures may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmaceutical CDMO. The growth and trends of Pharmaceutical CDMO industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmaceutical CDMO market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Infectious Diseases
Oncology
Neurological Disorders

By Workflow

Commercial
Clinical

By Product

Synthesis
Manufacturing
Drug
API

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmaceutical CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmaceutical CDMO market include WuXi AppTec, Catalent Inc., AbbVie Contract Manufacturing, Lonza Group AG, Evonik Industries AG, Patheon, Siegfried Holding AG, Recipharm AB, Aenova Group, CordenPharma, Jubilant Life Sciences Ltd., Almac Group, Piramal Pharma Solutions, Cambrex Corporation, Fareva. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PHARMACEUTICAL CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Workflow
- 3.7.3 Market Attractiveness Analysis By Product
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Infectious Diseases Historic and Forecast Sales By Regions
5.4. Oncology Historic and Forecast Sales By Regions
5.5. Neurological Disorders Historic and Forecast Sales By Regions

6. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY WORKFLOW

6.1. Overview By Workflow
6.2. Historical and Forecast Data Analysis By Workflow
6.3. Commercial Historic and Forecast Sales By Regions
6.4. Clinical Historic and Forecast Sales By Regions

7. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY PRODUCT

7.1. Overview By Product
7.2. Historical and Forecast Data Analysis By Product
7.3. Synthesis Historic and Forecast Sales By Regions
7.4. Manufacturing Historic and Forecast Sales By Regions
7.5. Drug Historic and Forecast Sales By Regions
7.6. API Historic and Forecast Sales By Regions

8. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL CDMO COMPANIES

9.1. Pharmaceutical CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PHARMACEUTICAL CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. WuXi AppTec
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Catalent Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. AbbVie Contract Manufacturing
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Lonza Group AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Evonik Industries AG
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Patheon
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Siegfried Holding AG
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Recipharm AB
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Aenova Group
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. CordenPharma
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Jubilant Life Sciences Ltd.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Almac Group
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Piramal Pharma Solutions
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Cambrex Corporation
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Fareva
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments